Monday morning pre-market screamer 😱 candidates: 🚨🚨🚨💎💎💎🔥🔥🔥 $TCBP Phase 2 update still pending-huge potential on this nano float $BOXD over $1 easy $ALLR PT $.50 $HTGM she’s ready for another big run This week was very good to me.

SIMILAR SETUP TO $AMAM, $HTGM, $APVO, $APCX Volume increasing since last week ✅ Low float recent IPO ✅ Strong future trial pipeline ✅ Time for the next leg up towards IPO price!

SHOULD be some awesome opportunities this week, study study study!

$ATNM positive news in their acute myeloid leukemia trials 👇🏼 53% 1-year Overall Survival and 32% 2-year Overall Survival are approximately double outcomes with current approaches It's time to get in before we blast off to $12+ next!

They are extremely confident and hired people to enter the big market of the USA , they have not stopped other trials they are in !!!!

but future is proving bright here via trials going into phase 2, old news here… let’s stay optimistic here, enjoy the ride. 🍻🍻

$TCBP sell now and miss huge news of phase 2b/3 results of 5 patients.. which will definitely be GREAT

Clinical trials have already shown incredible results and a full trial with 37 patients in ACHIEVE kicks off very soon.

main man owns 30 percent and he made a billion on moderna so we have s ’ pedegree’ this one should double or triple easily on good phase III!

Successful 2b/3 trial for cancer drug.

$TCBP they are in Phase 2/3.. everything is promising for the new drug it seems

Read the results from earlier studies. Astounding!!

Fast tracked, phase 3.

$MDGL this is the cream of the crop, we already have stellar phase 3 results in the books.

$MDGL nice opportunity to add a few hundred shares here 😆 the celebration of shorts today reminded me when the stock price dropped sharply by 27% in a couple of days before trial readout.

This is an outstanding setup for $VKTX's VK2809 P2b study which is scheduled to release data in Q2 2023.

Bullish going into Phase 3 next week!

$VKTX from what I've read from the preliminary trial data, the molecule is good, maybe better than $MDGL and has applications in weightloss.

Based on my multi year knowledge in NASH field, mdgl management so far did the best execution of clinical development - too many things to exemplify here!

Study results showed statistically significant absolute reductions in hepatic fat fraction at week 13 with pegozafermin administered every week or every two weeks compared to placebo.

After reaching its endpoints on its Phase 3 data we have seen a $240 spike!

Plus, remember this company is light years ahead of its competitors none of whom have had success with Phase 3. Bullish!

$VKTX Truth: VKTX increased more than 100% last 3 days since $MDGL has Phase 3 results.